As per MRFR analysis, the US C-Reactive Protein Testing Market Size was estimated at 478.95 (USD Million) in 2023. The US C-Reactive Protein Testing Market Industry is expected to grow from 512(USD Million) in 2024 to 1,065.58 (USD Million) by 2035. The US C-Reactive Protein Testing Market CAGR (growth rate) is expected to be around 6.89% during the forecast period (2025 - 2035).
In the US C-Reactive Protein Testing Market, there is a noticeable trend towards increased awareness of inflammation-related diseases among both healthcare providers and patients. This has been fueled by growing research linking elevated C-Reactive Protein (CRP) levels to conditions such as cardiovascular diseases and autoimmune disorders. The shift towards preventive healthcare is driving demand for CRP testing as a routine assessment tool. Additionally, advancements in diagnostic technology are improving the accuracy and efficiency of CRP tests, making them more accessible in various healthcare settings, including outpatient clinics and at-home testing platforms.
Key market drivers include the rise in chronic diseases, which necessitates ongoing monitoring of inflammatory markers. CRP testing serves as an essential component in managing conditions that are prevalent in the US population, such as heart disease, which is a leading cause of death. Furthermore, the healthcare system's movement towards value-based care is pushing healthcare practitioners to adopt testing methods that can provide actionable insights for patient management. Opportunities to be explored include expanding testing capabilities in telemedicine and at-home healthcare, catering to the growing number of patients seeking convenience and efficiency.
The pandemic has accelerated the acceptance of remote healthcare, leading to an increase in home testing solutions, including CRP tests. Collaborations between diagnostic companies and digital health platforms can streamline access to these tests and enhance patient engagement. Recent trends also highlight a focus on educational initiatives aimed at both healthcare providers and the public to promote understanding of the importance of CRP levels in health management. By improving education around inflammation and its health implications, there is potential to drive further growth in testing adoption and utilization across the United States.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The rise in various inflammatory diseases in the United States has significantly impacted the US C-Reactive Protein Testing Market Industry. According to the Centers for Disease Control and Prevention (CDC), over 50 million Americans are affected by arthritis, a leading cause of inflammation. Also, with more than 27 million adults suffering from osteoarthritis, the demand for C-Reactive Protein testing, which helps assess inflammation, is surging.
This spike in inflammatory disease cases is likely to fuel the demand for effective diagnostic tools, which are crucial in managing these conditions, thereby supporting the growth of the C-Reactive Protein testing market. Established organizations such as the American College of Rheumatology and the Arthritis Foundation are promoting awareness and research into these conditions, contributing to increased testing and diagnosis protocols for managing chronic inflammation.
There is a noticeable shift towards preventive healthcare in the United States, prompting individuals to seek regular health screenings. With a growing emphasis on proactive health measures, the demand for C-Reactive Protein tests is expected to rise, as they serve as an important indicator of inflammation linked with various chronic diseases. According to the National Institute of Health, preventive healthcare can reduce overall healthcare costs by up to 30 percent.
Established health organizations are advocating for routine inflammatory marker screenings as part of comprehensive health checks, further driving the growth of the US C-Reactive Protein Testing Market Industry.
Technological advancements in diagnostic tools have significantly improved the efficiency and accuracy of C-Reactive Protein Testing in the United States. Innovations such as high-sensitivity assays are now available, enabling more precise measurements of C-Reactive Protein levels. As per the Food and Drug Administration, there has been a notable increase in FDA-approved tests related to C-Reactive Protein.
Established entities like the American Association for Clinical Chemistry are continually promoting the integration of advanced technologies in laboratories, paving the way for enhanced testing capabilities.This trend not only meets the growing demand for rapid results but also reinforces the relevance of the US C-Reactive Protein Testing Market Industry in the healthcare sector.
The US C-Reactive Protein Testing Market is a critical segment of the healthcare industry, particularly in monitoring inflammation and disease activity in various clinical settings. The Assay Type classification within this market is multifaceted, encompassing various methodologies such as Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), and Immunoturbidimetric Assays, among others. ELISA is highly regarded for its sensitivity and specificity, making it a preferred choice in many laboratories for quantifying C-reactive protein levels, especially in autoimmune diseases and chronic inflammatory states.
Its user-friendly procedures and ability to conduct large sample analyses significantly boost its utilization in clinical practices across the US.Chemiluminescence Immunoassay (CLIA) also plays a pivotal role in the market due to its rapid processing time and enhanced detection capabilities. This assay type allows for the swift assessment of CRP levels, making it particularly beneficial in emergency departments and critical care settings where timely diagnosis is crucial for patient outcomes.
Additionally, CLIA often shows a lower limit of detection, further solidifying its importance in the monitoring of various diseases.Immunoturbidimetric Assays are gaining traction as they offer a straightforward method for CRP quantification, suitable for integration into automated systems in hospital laboratories. This assay type is ideal for high-throughput environments, thereby improving workflow efficiency, which is a considerable advantage in today's increasingly busy healthcare settings.
The "Others" category includes emerging assay technologies that may offer innovative approaches to CRP testing, focusing on enhanced accuracy and ease of use. These alternative methods could address some current limitations faced by traditional assays, potentially leading to increased adoption in clinical and research environments.Overall, the various Assay Type methodologies contribute significantly to the US C-Reactive Protein Testing Market by catering to diverse laboratory needs and conditions.
These technologies not only facilitate better patient management but also align with the growing trend of personalized medicine, further driving market opportunities and innovations in CRP assessment. The ongoing advancements and increasing demand for efficient testing methodologies are indicative of a vibrant market landscape, with considerable prospects for growth and enhanced diagnostic precision in patient care.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Application segment of the US C-Reactive Protein Testing Market plays a crucial role in diagnosing and managing various inflammatory and autoimmune conditions. C-Reactive Protein testing is pivotal for monitoring diseases such as Diabetes, where inflammation is often a key factor in disease progression. In Rheumatoid Arthritis, this testing aids in assessing disease activity and guiding treatment decisions, highlighting its significance in personalizing care.
Additionally, in Cardiovascular Disease, elevated C-Reactive Protein levels can indicate increased risk, making it essential for early intervention strategies.Inflammatory Bowel Disease also benefits from C-Reactive Protein testing, as it helps in monitoring flare-ups and treatment responses. The presence of other conditions in this segment illustrates the broad utility of C-Reactive Protein testing across diverse health issues. The growing awareness of the importance of inflammatory markers and their impact on health outcomes further drives the demand for C-Reactive Protein testing in the United States, establishing it as a vital tool in modern medical practice.
The US C-Reactive Protein Testing Market is characterized by significant competitive dynamics fueled by the increasing prevalence of inflammatory diseases and the growing emphasis on early diagnosis and preventive healthcare. Within this market, key players are actively participating in innovative product development and strategic partnerships to enhance their market positioning. The landscape is shaped by advancements in testing technologies and the rise in demand for high-sensitivity C-reactive protein tests, which serve as crucial markers for inflammatory conditions and cardiovascular risk assessments.
Companies are focusing on expanding their product portfolios and improving accessibility to testing services in response to the evolving needs of healthcare providers and patients alike. As competition intensifies, firms in this sector are also leveraging digital tools for data management and reporting to enhance patient outcomes and test accuracy, all while navigating regulatory frameworks.
Hologic stands out in the US C-Reactive Protein Testing Market with its strong presence and concentration on women's health, which does synergize with its offerings in the diagnostic space. The company's strengths lie in its robust research and development initiatives, which continually propel the innovation of its diagnostic capabilities. Hologic has developed advanced testing platforms that facilitate rapid and accurate CRP testing, catering to the specific needs of healthcare providers.
Furthermore, the company's integration of advanced technologies allows for optimized data management and patient interaction, making its products an integral part of clinical decision-making. Hologic's commitment to quality assurance and its ability to maintain compliance with regulatory requirements are additional factors that reinforce its competitive edge in the market.
BioRad Laboratories has established a notable presence in the US C-Reactive Protein Testing Market, primarily through its extensive portfolio of diagnostic solutions and laboratory instruments. The company offers a variety of key products related to C-reactive protein testing that have gained traction across healthcare settings due to their reliability and accuracy. BioRad Laboratories' strengths are derived from its expansive distribution network and established customer relationships, coupled with strategic collaborations that enable access to the latest technological advancements.
The company's focus on innovation is complemented by imperative mergers and acquisitions aimed at enhancing its overall market offerings and expanding its capabilities within the diagnostics space. With a strong commitment to supporting clinical laboratories, BioRad Laboratories remains dedicated to providing healthcare professionals with solutions that improve patient care and streamline operational efficiencies.
Recent developments in the US C-Reactive Protein Testing Market have seen increased demand for rapid diagnostic tests, especially in the wake of heightened health awareness post-pandemic. Companies like Hologic and Roche Holding are witnessing growth driven by advancements in their testing technologies. Collaborative efforts between firms such as Abbott Laboratories and Quest Diagnostics are enhancing the precision and accessibility of testing, thereby propelling market expansion.
Merger and acquisition activities in this space remain significant, with notable transactions including the acquisition of Hemosure by Siemens Healthineers in September 2023, aimed at strengthening their diagnostic portfolio, which has been widely covered by media outlets. In prior years, Labcorp expanded its testing capabilities with the acquisition of Genova Diagnostics in March 2022, bolstering their portfolio in inflammatory markers testing. The overall valuation of the market has surged, influenced by an increasing focus on early detection of diseases linked to inflammation, which C-Reactive Protein testing supports. This surge emphasizes the strategic movements within the market, particularly the collaborations and technological innovations being pursued by these key players, providing a vibrant landscape in the US C-Reactive Protein Testing Market.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 478.95(USD Million) |
| MARKET SIZE 2024 | 512.0(USD Million) |
| MARKET SIZE 2035 | 1065.58(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.89% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Hologic, BioRad Laboratories, Roche Holding, Mayo Clinic Laboratories, Abbott Laboratories, Beckman Coulter, Thermo Fisher Scientific, Genova Diagnostics, Hemosure, Siemens Healthineers, Quest Diagnostics, Ortho Clinical Diagnostics, Labcorp, ArcherDX, DiaSorin |
| SEGMENTS COVERED | Assay Type, Application |
| KEY MARKET OPPORTUNITIES | Growing demand for rapid testing, Increased chronic disease prevalence, Advancements in biomarker technologies, Expansion of point-of-care testing, Integration with telehealth services |
| KEY MARKET DYNAMICS | rising prevalence of chronic diseases, increasing awareness of inflammation, technological advancements in testing, growing demand for early diagnosis, favorable reimbursement policies |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The market is expected to be valued at 512.0 million USD in 2024.
By 2035, the market is projected to reach a value of 1,065.58 million USD.
The expected CAGR for the market during this period is 6.89%.
By 2035, the Chemiluminescence Immunoassay (CLIA) is projected to dominate the market with a value of 410.0 million USD.
The market value of Enzyme-linked Immunosorbent Assay (ELISA) is expected to reach 320.0 million USD by 2035.
Key players include Hologic, Roche Holding, Abbott Laboratories, and Quest Diagnostics among others.
Immunoturbidimetric Assays are projected to have a market value of 100.0 million USD in 2024.
The 'Others' segment is expected to reach a market size of 125.58 million USD by 2035.
Opportunities include advancements in testing technology and increasing awareness of inflammatory diseases.
The competitive landscape has intensified with new players entering the market and existing players expanding their product offerings.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
